Blue Trust Inc. Reduces Stake in Sana Biotechnology, Inc. $SANA

Blue Trust Inc. lowered its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 24.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 19,520 shares of the company’s stock after selling 6,397 shares during the quarter. Blue Trust Inc.’s holdings in Sana Biotechnology were worth $53,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Viewpoint Capital Management LLC lifted its holdings in Sana Biotechnology by 19.1% in the 2nd quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock worth $77,000 after buying an additional 4,500 shares during the period. Bank of New York Mellon Corp lifted its holdings in Sana Biotechnology by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock worth $578,000 after buying an additional 7,230 shares during the period. Hsbc Holdings PLC lifted its holdings in Sana Biotechnology by 26.5% in the 1st quarter. Hsbc Holdings PLC now owns 41,377 shares of the company’s stock worth $65,000 after buying an additional 8,673 shares during the period. Rhumbline Advisers lifted its holdings in Sana Biotechnology by 5.4% in the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock worth $306,000 after buying an additional 9,359 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Sana Biotechnology by 0.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,066,304 shares of the company’s stock worth $1,791,000 after buying an additional 9,792 shares during the period. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on SANA shares. Wedbush started coverage on Sana Biotechnology in a research report on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Morgan Stanley started coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Sana Biotechnology Stock Down 5.1%

SANA stock opened at $5.03 on Friday. Sana Biotechnology, Inc. has a twelve month low of $1.26 and a twelve month high of $7.30. The firm has a market cap of $1.20 billion, a PE ratio of -4.75 and a beta of 1.91. The business has a 50 day moving average of $3.55 and a 200 day moving average of $2.99.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. On average, research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.